<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097068</url>
  </required_header>
  <id_info>
    <org_study_id>ML39638</org_study_id>
    <nct_id>NCT03097068</nct_id>
  </id_info>
  <brief_title>Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis</brief_title>
  <official_title>Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitreo-Retinal Associates, Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vitreo-Retinal Associates, Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol will measure a number of cytokines in addition to vascular endothelial growth&#xD;
      factor in response to 0.3mg Lucentis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lucentis injections are the current standard of care for diabetic macular edema. The only&#xD;
      deviation from the standard of care in the current protocol is an aqueous tap before the&#xD;
      first Lucentis injection and the fourth Lucentis injection for diabetic macular edema.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Actual">February 2, 2018</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vascular endothelial growth factor levels</measure>
    <time_frame>One year</time_frame>
    <description>In aqueous</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>0.3 mg Lucentis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aqueous Humor sample post injection of 0.3 mg Lucentis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>0.3mg Lucentis</description>
    <arm_group_label>0.3 mg Lucentis</arm_group_label>
    <other_name>Aqueous Tap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus&#xD;
&#xD;
          -  Best corrected visual acuity 20/32 - 20/320&#xD;
&#xD;
          -  Diabetic macular edema involving the center of the macula&#xD;
&#xD;
          -  Optical coherence tomography central subfield thickness of at least 250 microns&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of anti-vascular endothelial growth factor treatment in the past 12 months&#xD;
&#xD;
          -  Any diabetic macular edema treatment in the past 4 months&#xD;
&#xD;
          -  Heart attack, stroke, transient ischemic attack or acute congestive heart failure&#xD;
             within 4 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vitreo-Retinal Associates, Michigan</investigator_affiliation>
    <investigator_full_name>Louis C Glazer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

